Zura Bio (NASDAQ:ZURA – Get Free Report) and Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.
Profitability
This table compares Zura Bio and Tvardi Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zura Bio | N/A | -55.74% | -48.07% |
| Tvardi Therapeutics | N/A | -64.17% | -43.90% |
Volatility and Risk
Zura Bio has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zura Bio | 1 | 1 | 4 | 1 | 2.71 |
| Tvardi Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
Zura Bio presently has a consensus target price of $10.75, suggesting a potential upside of 95.10%. Tvardi Therapeutics has a consensus target price of $24.29, suggesting a potential upside of 539.10%. Given Tvardi Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Zura Bio.
Institutional & Insider Ownership
61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Zura Bio and Tvardi Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zura Bio | N/A | N/A | -$99.35 million | ($1.09) | -5.06 |
| Tvardi Therapeutics | $7.14 million | 4.99 | -$18.21 million | ($3.10) | -1.23 |
Tvardi Therapeutics has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Tvardi Therapeutics beats Zura Bio on 8 of the 12 factors compared between the two stocks.
About Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
About Tvardi Therapeutics
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.
